{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=94",
    "query": {
      "condition": "Advanced Solid Neoplasm",
      "page": 94
    },
    "page_size": 10
  },
  "pagination": {
    "page": 94,
    "page_size": 10,
    "total_count": 3387,
    "total_pages": 339,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=95&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=93&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T22:11:05.748Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01948843",
      "title": "Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Negative Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2014-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01948843"
    },
    {
      "nct_id": "NCT03213691",
      "title": "Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma",
        "Recurrent Childhood Central Nervous System Neoplasm",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Primary Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 21,
      "start_date": "2017-10-30",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-02-05",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 108,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213691"
    },
    {
      "nct_id": "NCT06281678",
      "title": "A Study of IBI363 in Subjects with Advanced Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "IBI363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2024-04-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06281678"
    },
    {
      "nct_id": "NCT00088790",
      "title": "AZD5438 in Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "AZD5438",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-07",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2011-01-26",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088790"
    },
    {
      "nct_id": "NCT07266285",
      "title": "BTM-3566 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BTM-3566",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bantam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-12-10",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07266285"
    },
    {
      "nct_id": "NCT06819735",
      "title": "Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "DT-7012",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Domain Therapeutics Australia Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-06-25",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819735"
    },
    {
      "nct_id": "NCT05378425",
      "title": "A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Advanced Solid Tumor",
        "Metastatic Cancer",
        "Locally Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "NTX-1088",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nectin Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2022-09-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 3,
      "location_summary": "Duarte, California • New Orleans, Louisiana • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05378425"
    },
    {
      "nct_id": "NCT02458638",
      "title": "A Study of Atezolizumab in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2015-07-16",
      "completion_date": "2020-07-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-04",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 5,
      "location_summary": "New York, New York • Cleveland, Ohio • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02458638"
    },
    {
      "nct_id": "NCT07127874",
      "title": "A Study of PHN-012 in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer",
        "Pancreatic Cancer",
        "Lung Cancer (NSCLC)",
        "Advanced Cancer",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PHN-012",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pheon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2025-09-23",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07127874"
    },
    {
      "nct_id": "NCT05415098",
      "title": "Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nasopharyngeal Carcinoma",
        "Castrate Resistant Prostate Cancer",
        "Gastric Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Mesothelioma",
        "Sarcoma",
        "Non Hodgkin Lymphoma",
        "B Cell Lymphoma",
        "Epithelioid Sarcoma"
      ],
      "interventions": [
        {
          "name": "APG-5918",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2022-09-30",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-11-14T22:11:05.748Z",
      "location_count": 1,
      "location_summary": "Springdale, Arkansas",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05415098"
    }
  ]
}